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Background: In 2006, the Senegalese National Malaria Control Programme recommended artemisinin-based
combination therapy (ACT) as the first-line treatment for uncomplicated malaria. Since the introduction of ACT,
there have been very few reports on the level of resistance of P. falciparum to anti-malarial drugs. To determine
whether parasite susceptibility has been affected by the new anti-malarial policies, an ex vivo susceptibility and drug
resistance molecular marker study was conducted on local isolates obtained from the Centre de santé Elizabeth
Diouf (Médina, Dakar, Senegal).
Methods: The prevalence of genetic polymorphisms in genes associated with anti-malarial drug resistance, i.e.,
pfcrt, pfdhfr, pfdhps and pfmdr1, were evaluated for a panel of 165 isolates collected from patients recruited from 17
August 2010 to 6 January 2011. The malaria isolates were assessed for susceptibility to chloroquine (CQ); quinine
(QN); monodesethylamodiaquine (MDAQ), the active metabolite of amodiaquine; mefloquine (MQ); lumefantrine
(LMF); dihydroartemisinin (DHA), the active metabolite of artemisinin derivatives; and doxycycline (DOX) using the
Plasmodium lactate dehydrogenase (pLDH) ELISA.
Results: The prevalence of the in vitro resistant isolates, or isolates with reduced susceptibility, was 62.1% for MQ,
24.2% for CQ, 10.3% for DOX, 11.8% MDAQ, 9.7% for QN, 2.9% for LMF and 0% for DHA. The Pfcrt 76T mutation was
identified in 43.6% of the samples. The pfmdr1 86Y, 184F and 1246Y mutations were found in 16.2%, 50.0% and
1.6% of the samples, respectively. The pfdhfr 108N, 51I and 59R mutations were identified in 81.9%, 77.4% and
79.4% of the samples, respectively. The double mutant (108N and 51I) was detected in 75.5% of the isolates, and
the triple mutant (108N, 51I and 59R) was detected in 73.6% of the isolates. The pfdhps 437G, 436A and 613S
mutations were found in 54.4%, 38.6% and 1.2% of the samples, respectively. There was only one double mutant,
437G and 540E, and one quintuple mutant, pfdhfr 108N, 51I and 59R and pfdhps 437G and 540E. The prevalence of
the quadruple mutant (pfdhfr 108N, 51I and 59R and pfdhps 437G) was 36.7%.
Conclusions: The results of this study indicate that an intensive surveillance of the in vitro P. falciparum
susceptibility to anti-malarial drugs must be conducted in Senegal.
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During the past 20 years, many strains of Plasmodium
falciparum have become resistant to chloroquine and
other anti-malarial drugs [1]. One strategy for reducing
malaria prevalence is the use of drugs in combination.
Drug combinations help prevent the development of
resistance to each component drug and reduce the
overall transmission of malaria [2]. In response to
increasing chloroquine resistance, Senegal switched in
2004, to sulphadoxine-pyrimethamine with amodiaquine
as the first-line therapy. In 2006, the Senegalese National
Malaria Control Programme recommended artemisinin-
based combination therapy (ACT) as the first-line
treatment for uncomplicated malaria. The combination
sulphadoxine-pyrimethamine and amodiaquine treatment
was changed to artemether-lumefantrine and artesunate-
amodiaquine. Since 2006, more than 1.5 million ACT-
based treatments have been administered in Senegal [3]. In
2006, the Senegalese National Malaria Control Programme
also recommended testing for all suspected cases of malaria
with the P. falciparum histidine-rich protein 2 (PfHRP2)-
based rapid diagnostic test (RDT). Since this time, ACT use
has been restricted to confirmed malaria cases to reduce
drug pressure. In 2009, 184,170 doses of ACT were dis-
pensed in Senegal [4].
Malaria is transmitted in Dakar and its surrounding
suburbs with a spatial heterogeneity of the human biting
rate, which ranged from 0.1 to 250 bites per person per
night during the rainy season from 2007 to 2010 [5,6].
In 2008 to 2009, the human biting rate was 0.7 bites per
person per night during the rainy season in Médina, a
district of the south of Dakar [5]. In 2008, the P. falciparum
prevalence varied from 0.9% to 7.4% in asymptomatic
women and children in Dakar [7]. Morbidity in public
health facilities decreased from 17.9% in 2007 to 2.6% in
2008 in Dakar [8].
Since the introduction of ACT, there have been very
few reports on the level of resistance of P. falciparum to
anti-malarial drugs. To determine whether parasite
susceptibility has been affected by the new anti-malarial
policies, an ex vivo susceptibility study was conducted
on local isolates from Dakar obtained from the Centre
de santé Elizabeth Diouf (Médina, Dakar, Senegal). The
malaria isolates were assessed for susceptibility to chloro-
quine (CQ), quinine (QN), monodesethylamodiaquine
(MDAQ), the active metabolite of amodiaquine, meflo-
quine (MQ), lumefantrine (LMF), dihydroartemisinin
(DHA), the active metabolite of artemisinin derivatives
and doxycycline (DOX).
In addition, the prevalence of genetic polymorphisms in
genes associated with anti-malarial drug resistance was
evaluated. The genes of interest included P. falciparum CQ
resistance transporter (pfcrt) for CQ [9], P. falciparum
dihydrofolate reductase (pfdhfr) for pyrimethamine [10], P.falciparum dihydropteroate synthase (pfdhps) for
sulphadoxine [11] and P. falciparum multidrug re-
sistance 1 (pfmdr1) for mefloquine resistance [12]
and potentially for quinoline resistance [13,14].
The pfcrt gene was first identified in 2000 [9]. To date, at
least 20 point mutations have been described [9,15,16], but
only one is the reference mutation (K76T), which is a
marker of the CQ-resistant phenotype. This mutation is
often associated with other mutations in the pfcrt gene,
whose role is not yet defined. The odds ratio (OR) for CQ
failure associated with the 76T mutation was 2.1 (95% con-
fidence interval: 1.5-3.0, meta-analysis of 13 studies) for a
14-day follow-up and 7.2 (95%CI: 4.5-11.5, meta-analysis of
12 studies) for a 28-day follow-up [17]. However, the exist-
ence of CQ-susceptible strains associated with the 76T
mutation suggests that other genes could be involved in the
resistance to chloroquine.
The S108N mutation in the pfdhfr gene is associ-
ated with resistance to anti-folate drugs [18]. The
OR for sulphadoxine-pyrimethamine failure associ-
ated with S108N was 3.5 (95%CI: 1.9-6.3, meta-
analysis of 10 studies) for a 28-day follow-up [17].
The additional mutations N51I, C59R or I164L increase the
level of in vitro resistance to anti-folate drugs and
sulphadoxine-pyrimethamine. The OR values for codon 51
and 59 single mutants were 1.7 (95%CI: 1.0-3.0) and 1.9
(95%CI: 1.4-2.6), respectively [17]. The triple mutation (51
+ 59 + 108) increases the risk of in vivo resistance to
sulphadoxine-pyrimethamine by 4.3 (95%CI: 3.0-6.3,
meta-analysis of 22 28-day studies) [17].
Sulphones (dapsone) and sulphonamides (sulphadoxine)
are inhibitors of the P. falciparum DHPS [19]. The muta-
tions S436A, S436F, A437G and K540E are involved in re-
sistance to sulphadoxine [11]. The single mutation A437G
and the double mutation A437G+K540E increase the risk
of in vivo resistance to sulphadoxine-pyrimethamine by 1.5
(95%CI: 1.0-2.4, meta-analysis of 12 studies) and 3.9 (95%
CI: 2.6-5.8, meta-analysis of 10 studies), respectively [17].
The quintuple mutant of pfdhfr (codons 51 + 59 + 108)
plus pfdhps (codons 437 + 540) increases the risk of
in vivo resistance to sulphadoxine-pyrimethamine by 5.2
(95%CI: 3.2-8.8, meta-analysis of 3 studies) [17]. Pfmdr1,
which encodes a 162 kDa protein named P. falciparum
homologue of the P-glycoprotein (Pgh1), is located on
chromosome 5. Field work has shown that the predictive
value for CQ resistance and point mutations in the
pfmdr1 sequence resulting in amino acid changes varies
depending on the geographic area [20,21]. Five point
mutations have been described: N86Y, Y184F, S1034C,
N1042D and D1246Y. Point mutations, most notably
N86Y, have been associated with a decrease in the CQ
susceptibility [22]. However, in some of these epidemio-
logical studies, the number of CQ-susceptible samples is
too limited to provide a statistically meaningful analysis
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relationships are established between CQ resistance and
mutations in pfmdr1 in P. falciparum [24]. However, the
risk of therapeutic failure with CQ is greater for patients
harbouring the 86Y mutation, with an OR of 2.2 (95%CI:
1.6-3.1) for a 14-day follow-up and 1.8 (95%CI: 1.3-2.4)
for a 28-day follow-up [17]. The combination of pfmdr1
86Y and pfcrt 76T increases the risk of in vivo resistance
to CQ by 3.9 (95%CI: 2.6-5.8, meta-analysis of 5
studies) [17].
In addition, the risk of therapeutic failure with
amodiaquine is greater for patients harbouring the 86Y
mutation with an OR of 5.4 (95%CI: 2.6-11.2, meta-
analysis of six studies) [17]. This mutation increases the
risk of failure with amodiaquine plus sulphadoxine-
pyrimethamine by 7.9 [25].
It has been shown through heterologous expression
that pfmdr1 mutations at codons 1034 and 1042 abolish
or reduce the level of resistance to mefloquine [26].
Moreover, transfection with a wild-type pfmdr1 allele at
codons 1034, 1042 and 1246 confers mefloquine resist-
ance to susceptible parasites [27]. However, mutations at
codons 1034, 1042 and 1246 of Pfmdr1 in P. falciparum
isolates are not sufficient to explain variations in meflo-
quine susceptibility [28]. Analyses of P. falciparum
isolates showed an association between mutation at
codon 86 and an increase in susceptibility to mefloquine,
halofantrine or artemisinin derivatives [12,29,30].
Methods
Plasmodium falciparum isolates
In total, 165 patients (63 females, 3 to 70 years old and
102 males, 2 to 67 years old) with malaria were recruited
from 17 August 2010 to 6 January 2011 at the Centre de
santé Elizabeth Diouf. Venous blood samples were
collected in VacutainerW ACD tubes (Becton Dickinson,
Rutherford, NJ, USA) prior to patient treatment and
transferred to the Hôpital Principal de Dakar within six
hours. Parasitaemia ranged from 0.001% to 20% in the
male group and from 0.001% to 10.6% in the female
group. Informed verbal consent was obtained from pa-
tients and/or their parents before blood collection. As-
sessment of P. falciparum susceptibility to anti-malarial
drugs was realised with the same venous blood sample
used for diagnostic purposes. The study was reviewed
and approved by the ethical committee of the Pasteur
Institute and the Hôpital Principal de Dakar. Patients
were treated by artemether-lumefantrine or artesunate-
amodiaquine (depending on availability).
Thin blood smears were stained using a RAL kit
(Réactifs RAL, Paris, France) and were examined to
determine the P. falciparum density and to confirm
monoinfection. Parasitized erythrocytes were washed
three times in RPMI 1640 medium (Invitrogen, Paisley,UK) buffered with 25 mM HEPES and 25 mM NaHCO3.
If parasitaemia exceeded 0.5%, infected erythrocytes
were diluted to 0.5% with uninfected erythrocytes (hu-
man blood type A+) and re-suspended in RPMI 1640
medium supplemented with 10% human serum (Abcys
S.A. Paris, France), for a final haematocrit of 1.5%.Drugs
CQ, QN, DHA and DOX were purchased from Sigma
(Saint Louis, MO, USA). MDAQ was obtained from the
World Health Organization (Geneva, Switzerland), MQ
was purchased from Roche (Paris, France), and LMF was
purchased from Novartis Pharma (Basel, Switzerland).
QN, MDAQ, MQ, DHA and DOX were first dissolved
in methanol and then diluted in water to final concen-
trations ranging from 5 nM to 3200 nM for QN, 1.56
nM to 1000 nM for MDAQ, 3.2 nM to 400 nM for MQ,
0.1 nM to 100 nM for DHA and 0.1 μM to 502 μM for
DOX. CQ was re-suspended and diluted in water to final
concentrations ranging from 5 nM to 3200 nM. LMF
was re-suspended and diluted in ethanol to obtain final
concentrations ranging from 0.5 nM to 310 nM.
The batches of plates were tested and validated on the
CQ-susceptible 3D7 strain (West-Africa) and the CQ-
resistant W2 strain (Indochina) (MR4, Virginia, USA) in
3 to 6 independent experiments using the same condi-
tions described in the paragraph below. The two strains
were synchronised twice with sorbitol before use [31],
and clonality was verified every 15 days using PCR geno-
typing of the polymorphic genetic markers msp1 and
msp2 and microsatellite loci [32,33] and each year by an
independent laboratory from the Worldwide Anti-
malarial Resistance Network (WWARN).Ex vivo assay
For the in vitro isotopic microtests, 200 μl of synchron-
ous parasitized red blood cells (final parasitaemia, 0.5%;
final haematocrit, 1.5%) was aliquoted into 96-well plates
pre-dosed with anti-malarial drugs. The plates were
incubated in a sealed bag for 42 h at 37°C with the at-
mospheric generators for capnophilic bacteria, Genbag
CO2W at 5% CO2 and 15% O2 (BioMérieux, Marcy l’Etoile,
France) [34]. After thawing the plates, haemolysed cultures
were homogenised by vortexing the plates. Both the success
of the drug susceptibility assay and the appropriate volume
of haemolysed culture to use for each assay were deter-
mined for each clinical isolate during a preliminary pLDH
ELISA. This pre-test and the subsequent ELISAs were
performed using a commercial kit (ELISA-Malaria antigen
test, ref 750101, DiaMed AG, Cressier, Morat, Switzerland)
as previously described [35]. The optical density (OD) of
each sample was measured with a spectrophotometer
(Multiskan EX, Thermo Scientific, Vantaa, Finland).
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hibit 50% of parasite growth (IC50) was calculated with
the inhibitory sigmoid Emax model, with estimation of
the IC50 through non-linear regression using a standard
function of the R software (ICEstimator version 1.2)
[36]. IC50 values were validated only if the OD ratio (OD
at concentration 0 / OD at concentration max) was
greater than 1.8 and the confidence interval ratio (upper
95% confidence interval of the IC50 estimation/lower
95% confidence interval of the IC50 estimation) was less
than 2.0 [36].
Nucleic acid extraction
The total genomic DNA of each strain was isolated
using the QIAampW DNA Mini kit according to the
manufacturer’s recommendations (Qiagen, Germany).
Pfcrt single-nucleotide polymorphisms (SNPs)
A 546-nucleotide fragment of the pfcrt gene (containing
codon 76) was amplified by PCR using CRTP1-sense
50-CCG TTA ATA ATA AAT ACA CGC AG-30 and
CRTP1-antisense 50-CGG ATG TTA CAA AAC TAT
AGT TAC C-30 primers [37]. The reaction mixture for
PCR amplifications included 2.5 μl of genomic DNA, 2.5
μl of 10X reaction buffer (Eurogentec), 0.5 μM of each
primer, 200 μM of a deoxynucleoside triphosphate
mixture (dGTP, dATP, dTTP and dCTP) (Euromedex,
Souffelweyersheim, France), 2.5 mM MgCl2 and 1 unit
of RedGoldStarW DNA polymerase (Eurogentec) in a
final volume of 25 μl. The thermal cycler (T3 Biometra,
Archamps, France) was programmed as follows: an
initial 94°C incubation for 5 min; 40 cycles of 94°C for
20 sec, 56°C for 20 sec and 60°C for 40 sec; and a final
5-min extension step at 60°C. The PCR products were
loaded on a 1.5% agarose gel containing 0.5 μg/mL
ethidium bromide. The PCR products were diluted
1:100 in distilled water, and 2.5 μl of the final dilution
was used for the second PCR. This PCR amplified a 275
bp segment around the mutation using a common inner
primer CRTP3-sense 50-TGA CGA GCG TTA TAG AG-
30 coupled with either CRTP4m-antisense 50-GTT CTT
TTA GCA AAA ATT G-30 (detects the 76T codon), or
CRTP4w-antisense 50-GTT CTT TTA GCA AAA ATT
T-30 (detects the 76K codon) [15]. The reaction mixture
for the PCR amplifications included 2.5 μl of diluted
PCR product, 2.5 μl of 10X reaction buffer (Eurogentec),
0.5 μM of each primer, 200 μM deoxynucleoside
triphosphate mixture, 1.5 mM MgCl2 and 0.75 U of
RedGoldStarW DNA polymerase (Eurogentec) in a final
volume of 25 μl.
The PCR conditions were as follows: initiation at 94°C
for 5 min; 15 cycles at 94°C for 20 sec, 48.5°C for 20 sec
and 64°C for 40 sec; and a final 5 min extension step at
64°C. Purified genomic DNA from P. falciparum clones3D7 (chloroquine sensitive) and W2 (chloroquine resist-
ant) were used as positive controls, and water and hu-
man DNA were used as negative controls. The PCR
products from the amplification reactions were evaluated
by electrophoresis on 2% agarose gels.
Pfmdr1 SNPs
Two primer pairs were used to amplify pfmdr1 frag-
ments carrying the five key codons [38]. A 590-base pair
fragment was amplified with the primer pair sense 50-
AGA GAA AAA AGA TGG TAA CCT CAG-30 and
antisense 50-ACC ACA AAC ATA AAT TAA CGG-30 to
determine the sequences of codons 86 and 184 (MDR1-1),
and a second fragment (968 base pairs) was amplified
with the primer pair sense 50-CAG GAA GCA TTT
TAT AAT ATG CAT-30 and antisense 50-CGT TTA
ACA TCT TCC AAT GTT GCA-30 to determine the
sequences of codons 1034, 1042, and 1246 (MDR1-2)
[38]. The reaction mixture consisted of approximately
2.5 μl of genomic DNA, 0.5 μM of forward and reverse
primers, 2.5 μl of 10X reaction buffer (Eurogentec), 2.5
mM MgCl2, 200 μM deoxynucleoside triphosphate
mixture (dGTP, dATP, dTTP and dCTP) (Euromedex,
Souffelweyersheim, France) and 1 U of RedGoldStarW
DNA polymerase (Eurogentec) in a final volume of 25 μl.
The thermal cycler (T3 Biometra) was programmed for
MDR1-1 as follows: an initial step at 94°C for 5 min; 40
cycles of 94°C for 30 sec, 52°C for 30 sec and 72°C for
1 min; and a final 10-min extension step at 72°C. For
MDR1-2 the parameters were as follows: an initial step
at 94°C for 5 min; 40 cycles of 94°C for 30 sec, 56°C for
1 min and 72°C for 1 min 30 sec; and a final 10-min
extension step at 72°C. The PCR products were loaded
on a 1.5% agarose gel containing 0.5 μg/mL ethidium
bromide. Amplicons were purified using the QIAquick
96 PCR BioRobot Kit and an automated protocol on
the BioRobot 8000 workstation (Qiagen, Courtaboeuf,
France). The purified fragments were sequenced
using the BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems) using the primers described
above. The sequencing reaction products were puri-
fied using the BigDye XTerminatorW Purification Kit
(Applied Biosystems) in accordance with the manu-
facturer’s instructions. The purified products were
sequenced using an ABI Prism 3100 analyser (Applied
Biosystems). The sequences were analysed using Vector
NTI advance (TM) software (version 11, Invitrogen, Cergy
Pontoise, France).
Pfdhfr SNP
A 562-bp fragment corresponding to the coding region
of pfdhfr was amplified using the following primers:
sense 50-ACG TTT TCG ATA TTT ATG C-30 and anti-
sense 50 TCA CAT TCA TAT GTA CTA TTT ATT C-30
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DNA, 2.5 μl of 10X reaction buffer (Eurogentec), 0.5 μM
each primer, 2.5 mM MgCl2, 200 μM deoxynucleoside
triphosphate mixture (dGTP, dATP, dTTP and dCTP)
(Euromedex, Souffelweyersheim, France) and 1 U of
RedGoldStarW DNA polymerase (Eurogentec) in a final
volume of 25 μl. The PCR conditions were as described
in [39]. The amplified fragments were purified, se-
quenced (with the primers used for PCR) and analysed
as described above.
Pfdhps SNP
A 672-bp fragment corresponding to the coding region
of pfdhps was amplified using the following primers:
sense 50-GTT GAA CCT AAA CGT GCT GT-30 and
antisense 50-TTC ATC ATG TAA TTT TTG TTG TG-
30 [39]. The fragment was amplified as described for
pfdhfr, and the PCR conditions were as described in
[39]. The amplified fragments were purified, sequenced
(with the primers used for PCR) and analysed as de-
scribed above.
Data and statistical analysis
IC50 values were analysed after logarithmic transform-
ation and expressed as the geometric mean of the IC50
and a confidence interval of 95% (CI95%). Using the
Plasmodium lactate dehydrogenase (pLDH) ELISA
under Genbag conditions, the cut-off values for in vitro
resistance, or reduced susceptibility, were 77 nM, 61
nM, 115 nM, 12 nM, 611 nM, 30 nM and 37 μM for
CQ, MDAQ, LMF, DHA, QN, MQ and DOX, respect-
ively [40].
Results
Out of the 165 patients recruited at the Centre de santé
Elizabeth Diouf, 63 were tested ex vivo, and 34 isolates
were successfully cultured. The average parameter esti-
mates for the seven anti-malarial drugs utilised againstTable 1 Ex vivo susceptibility of 34 Plasmodium falciparum iso
monodesethylamodiaquine (MDAQ), lumefantrine (LMF), dihy
and doxycycline (DOX)
Drug No Isolate IC50
Mean CI95% Min
CQ 34 41.3 nM 26.7-64.0 5.1
MDAQ 34 19.4 nM 13.3-28.4 1.6
LMF 34 9.8 nM 6.3-15.2 0.77
DHA 32 3.6 nM 2.8-4.6 1.2
QN 34 141.3 nM 93.7-213.0 5.2
MQ 32 30.1 nM 22.2-41.0 5.3
DOX 32 9.2 μM 6.5-12.9 0.5
Mean: geometric mean.
CI95%: 95% confidence interval.the P. falciparum isolates are given in Table 1. The
prevalence of P. falciparum isolates with decreased
susceptibility to MQ in vitro reached 62.1%.
Pfcrt was examined in 156 of the samples. Within the
pfcrt gene, the 76T mutation was identified in 43.6% of
the samples. Eighteen samples (10.3%) were mixed,
yielding both K76 and 76T.
The results for pfmdr1 polymorphisms are shown in
Table 2. The 86Y mutation was identified in 14.9% of
the tested samples. A mutation in codon 184 (184F) was
identified in 49.4% of the isolates. Eighteen of the 24
isolates with the 86Y mutation were also mutated at
codon 184 (184F). No new SNP was detected in the
pfmdr1 gene.
The results for pfdhfr polymorphisms are presented in
Table 3. There was a mutation in 81.9% of the samples
for codon 108 (S108N/T), in 77.4% for codon 51 (N51I)
and in 79.4% for codon 59 (C59R). The double mutant
(108N and 51I) was detected in 75.5% of the isolates,
and the triple mutant (108N, 51I and 59R) was detected
in 73.6% of samples.
The results for the pfdhps polymorphisms are presented
in Table 4. There was a mutation in 47.5% of the samples
for codon 437 (A437G), in 33.5% for codon 436 (S436A),
in 1.2% for codon 613 (A613S) and in 0.6% for codon 540
(K540E). There was only one (0.6%) double mutant (437G
and 540E) and one (0.6%) quintuple mutant (pfdhfr 108N,
51I and 59R and pfdhps 437G and 540E), and 58 isolates
(36.7%) were quadruple mutants (pfdhfr 108N, 51I and
59R and pfdhps 437G).
Discussion
This report describes the evaluation of the ex vivo sus-
ceptibility of P. falciparum isolates, taken from patients
in Dakar, to seven standard anti-malarial drugs and the
prevalence of several molecular markers involved in
anti-malarial drug resistance. The majority of the pa-
tients, recruited at the Centre de santé Elizabeth Diouflates from Dakar to chloroquine (CQ),
droartemisinin (DHA), quinine (QN), mefloquine (MQ)
Resistance or reduced susceptibility
Max Cut-off %
1958 77 nM 24.2
179 61 nM 11.8
139 115 nM 2.9
11.0 12 nM 0
1195 611 nM 9.7
86.9 30 nM 62.1
41.9 37 μM 10.3
Table 2 Number (no) and frequency (%) of the Pfmdr1 mutations (codons 86, 184, 1034, 1042, and 1246)
Codon No Wild type no (%) Mutated no (%) Wild type/Mutated no (%)
N86Y 161 135 (83.9) 24 (14.9) 2 (1.2)
Y184F 156 78 (50.0) 77 (49.4) 1 (0.6)
S1034C 153 153 (100) 0 (0) 0 (0)
N1042D 156 156 (100) 0 (0) 0 (0)
D1246Y 156 154 (98.7) 2 (1.3) 0 (0)
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that they did not leave Dakar and its surrounding sub-
urbs during the month preceding their malaria attack.
The prevalence of isolates with reduced susceptibility
to MQ remains high (62.1%) in Dakar, but relatively
stable compared with the previous year (55%) [40]. The
level of in vitro resistance to MQ has increased since
previous studies conducted in Senegal. In Dakar, the
percent of isolates with decreased susceptibility was 17%
in 2001 [41] and 13% in 2002 [33]. In Dielmo and Ndiop
(280 km south-east of Dakar), the prevalence of in vitro
resistance to MQ was 22% in 1995 [42] and 15% in 1999
[43,44]. Prophylaxis failure with MQ has been previously
described in Senegal [45], and MQ is one of the three
anti-malarial drugs recommended for travellers as an
anti-malarial prophylaxis in Senegal. Clinical trials are in
progress to evaluate the efficacy of MQ for intermittent
preventive treatment of infants and pregnant women,
while MQ is still used for the treatment of uncompli-
cated malaria in infants in Dakar. Nevertheless, MQ has
been employed relatively infrequently in Africa compared
to Asia. The combination of artesunate-mefloquine, which
is administered to patients in Asia, is not yet used in
Senegal. However, scientific data are not available for MQ
monotherapy, and very few data are available on the
in vitro decreased susceptibility to MQ and its clinical
implications in Africa. It is important to monitor the evolu-
tion of P. falciparum susceptibility to MQ, to archive
suspicious isolates and to correlate clinical outcomes with
pharmacokinetic and phenotypic responses and with
molecular markers.
As far back as 1988, in vitro P. falciparum resistance
to CQ was reported in Dakar, and reports of resistance
in other regions of the country followed shortly [46].
From 1991 to 1995, parasitological failures were observedTable 3 Number (no) and frequency (%) of the Pfdhfr
mutations (codons 108, 51, 59, 16, and 164)
Codon no Wild type no (%) Mutated no (%)
S108N 155 28 (18.1) 127 (81.9)
N51I 155 35 (22.6) 120 (77.4)
C59R 155 32 (20.6) 123 (79.4)
A16V 155 155 (100) 0 (0)
I164L 153 153 (100) 0 (0)in 21% of patients in Pikine and in 23% of patients in
another region of Senegal [47]. The in vitro resistance to
CQ increased from 1995 to 1999 in Dielmo with 32%
resistance in 1995 [48] compared to 49% resistance in
1996 [49], 44% resistance in 1997 [50] and 55% resist-
ance in 1999 [43]. In 2010, the prevalence of in vitro
resistance to CQ in Dakar was low and stable in com-
parison with the previous year (24.2% versus 22%) [40].
These data are consistent with previous work on in vitro
resistance in Thies in 2007 (23% of isolates exhibiting
CQ resistance) [51]. The evolution of susceptibility to
CQ is confirmed by evaluation of molecular markers of
CQ resistance, and mutations in pfcrt have been shown
to be correlated with CQ resistance in different parts of
the world [52]. The prevalence of the pfcrt 76T mutation
has decreased since 2004 in Dakar. From 2000 to 2001
in Guediawaye, a suburb of Dakar, a prevalence of 92%
of was observed for the 76T mutation in pregnant
women with malaria [53]. In Pikine, another suburb of
Dakar, the prevalence of the 76T mutant was 79% in
2000 [54], 63.9% in 2001 [55] and 59.5% in 2004 [56]. In
2002, the prevalence of the pfcrt 76T mutation was 65%
in patients hospitalised for malaria at the Hôpital
Principal de Dakar [33]. From 2001 to 2002, the preva-
lence of the pfcrt 76T mutation was 75.8% in pregnant
women taking chloroquine prophylaxis in Thiadiaye
(84 km southeast of Dakar) [57]. In this study, the
pfcrt 76T mutation was identified in 43.6% of the
patients recruited from August 2010 to January 2011.
These data are consistent with previous works on CQ
molecular resistance in Dakar in 2009 (37.8%) [58], in
central Senegal (Mbour, Fatick and Bambey) in 2009
(29.3%) and in 2010 (25.1%); and in south Senegal
(Tambacounda, Velingara and Saraya) with 2010
(34.5%) and in 2011 (28.8%) [59]. However, in Pikine,
the prevalence of the pfcrt 76T mutation ranged from
64% to 79% before CQ withdrawal (2000 to 2003)
[54,55,60], the prevalence then decreased to 47-60% [56,60]
while amodiaquine plus pyrimethamine-sulphadoxine was
the first-line treatment (2004–2005); this prevalence has
increased slightly to 59% since ACT has been implemented
(2006 to 2009) [60].
This decrease in CQ resistance parallels the with-
drawal of CQ treatment and the introduction of ACT in
2002 in Senegal. However, in 2003, CQ was still being
Table 4 Number (no) and frequency (%) of the Pfdhps mutations (codons 437, 436, 540, 581, and 613)
Codon no Wild type no (%) Mutated no (%) Wild type/Mutated no (%)
A437G 158 72 (45.6) 75 (47.5) 11 (6.9)
S436A 158 97 (61.4) 53 (33.5) 8 (5.1)
K540E 160 159 (99.4) 1 (0.6) 0 (0)
A581G 160 160 (100) 0 (0) 0 (0)
A613S 160 158 (98.8) 2 (1.2) 0 (0)
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urine ranged from 14.5% to 47.5% in two- to nine-year
-old children from northern Senegal and from 9.0% to
21.4% in children from southern Senegal [61]. In 2006,
the Senegalese National Malaria Control Programme
recommended ACT as the first-line treatment for un-
complicated malaria, in this same year, Senegal reported
10.6% chloroquine use and 9.7% ACT use [62]. In Dakar
in 2006, CQ represented 5.1% of the anti-malarial drugs
used in children [63] and 3.5% in 2009 [64]. Since 2006,
more than 1.5 million ACT treatments have been ad-
ministered in Senegal [3], and 184,170 doses of ACT
were dispensed in 2009 [4]. A reduction in CQ resist-
ance was also reported in Malawi after the withdrawal of
CQ treatment [65]. This observation prompted an
in vivo CQ study in Malawi five years later, in which CQ
was found to be 99% effective [66]. The rapid dissemin-
ation of CQ resistance in Dielmo, despite strictly
controlled anti-malarial drug use, argues against the re-
introduction of CQ, at least in mono-therapy, in places
where the resistant allele has dropped to very low levels
following the discontinuation of CQ treatment [67].
Despite the regain of CQ susceptibility, any reintro-
duction would likely result in a rapid re-emergence
of resistant strains.
The prevalence of isolates with in vitro reduced
susceptibility to MDAQ slightly increased in 2010, 11.8%
versus 6% in 2009 [40]. The prevalence of reduced
susceptibility to MDAQ was 0% in 1996 and 1999 in
Dielmo [44,48], while it was 5% in Mlomp (Casamance,
south-western Senegal) in 2004 [68].
The prevalence of the pfmdr1 mutations 86Y, 184F
and 1246Y were 16.2%, 50.0% and 1.6%, respectively. In
2000 and 2001, prevalence rates of 31% and 30.6%,
respectively, were observed for pfmdr1 86Y in Pikine
[54,55], and a prevalence rate of 17.2% was observed in
Dakar in 2009 [58]. However, the role of polymorphism
in pfmdr1 is still debated. The pfmdr1 86Y mutation has
been shown to be associated with in vivo resistance to
amodiaquine in recrudescence after monotherapy with
amodiaquine [69] or after combination therapy with
artesunate-amodiaquine [70]. The pfmdr1 1246Y mutation
has also been found to be associated with in vitro resistance
to amodiaquine [71] and with recrudescent infection after
treatment with amodiaquine or amodiaquine-artesunate[70,72]. In a meta-analysis, the pfmdr1 86Y mutation was
found to be associated with amodiaquine failure, with an
odds ratio of 5.4 [17]. Based on this hypothesis, the 16.2%
prevalence of pfmdr1 of 86Y predicts that 16.2% of isolates
would be resistant to amodiaquine in 2010 in Senegal. The
resistance to amodiaquine has remained low even after the
introduction of artesunate-amodiaquine in 2006 in Senegal.
A study in Dakar and Mlomp from 1996 to 1998
showed that monotherapy with amodiaquine remained
effective for treating uncomplicated malaria in areas
where CQ resistance was prevalent [73]. The artesunate-
amodiaquine–associated cure rates were > 99.3% in Mlomp
and Keur-Socé when administered either as a single daily
dose or as two daily doses [74]. The fixed-dose combination
of artesunate-amodiaquine (ASAQ) exhibits a cure rate >
98.5% [75]. However, ACT efficacy and resistance must be
monitored because clinical failures, or at least extended
parasite clearance times, have been described in Cambodia
[76,77]. In this context, it is important to implement
in vitro and in vivo surveillance programmes, such as those
championed by the Worldwide Antimalarial Resistance
Network [78,79].
No isolate exhibited reduced in vitro susceptibility to
DHA. This result is consistent with previous studies that
did not show any parasites resistant to artesunate
[33,43,44]. However, Agnamey et al. reported that 3% -
23% of isolates had IC50 values greater than 15 nM in
Mlomp between 2000 and 2004 [73]. High IC50 values
can also be found for artemisinin, with an IC50 > 30 nM
in Dakar [51] and artesunate with an IC50 > 45 nM [41].
The other ACT first-line treatment for uncomplicated
P. falciparum malaria in Senegal is the combination of
artemether-lumefantrine. Only 2.9% of the isolates
presented reduced susceptibility to LMF, and this preva-
lence did not rise in Senegal after the introduction of
ACT. In 1996, 6% of isolates from Dielmo were resistant
to LMF in vitro [80]; and 1% of the isolates were resist-
ant to LMF in 2009 in Dakar [40].
In 2009, 7% of isolates showed low reduced suscepti-
bility to QN, which is in accordance with previous stud-
ies in Dakar [33,40,41] and Dielmo [42-44]. Isolates with
a high IC50 to QN were already identified in 1984 [81].
Even in areas where QN efficacy remains good, such as
sub-Saharan Africa, the susceptibility of individual P.
falciparum isolates to QN has varied widely. The IC50s
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1984 (Thies and Kaolack) [81], 5 to 932 nM in 1996
(Dielmo) [49] and 6 to 1291 nM in 2009 (Dakar) [40].
The wide range in QN susceptibility and recent evidence
for QN treatment failure seen across Africa [82,83] or in
Senegal in a patient who spent two months in Dielmo in
2007 [84] suggest that the evolution of parasites with
reduced susceptibility may contribute to QN decreased
efficacy. QN used in combination with DOX in the
treatment of severe malaria in Dakar.
A prevalence of 10.3% of isolates with in vitro reduced
susceptibility to DOX was observed in Dakar in 2010,
which is similar to the prevalence observed in 2009
(12%) [40]. The mean IC50 of DOX was similar to those
estimated in Dielmo in 1998 [85,86]. The slow activity of
DOX in vitro has a delayed effect upon growth and
requires the prolonged incubation of parasites [85,87].
However, the standard 42 h test is still used to monitor
DOX in vitro susceptibility.
The pfdhfr 108N mutation has been shown to be corre-
lated with in vitro and in vivo resistance to pyrimethamine
[10,17]. The OR for sulphadoxine-pyrimethamine failure
associated with Ser108Asn has been shown to be 3.5 (95%
CI: 1.9-6.3, meta-analysis of 10 studies) for a 28-day follow-
up [17]. The additional mutations N51I, C59R or I164L in-
crease the level of in vitro resistance to anti-folate drugs
and sulphadoxine-pyrimethamine. The OR values for single
mutants of codons 51 and 59 are 1.7 (95%CI: 1.0-3.0) and
1.9 (95%CI: 1.4-2.6), respectively [17]. In 2010, the preva-
lence of pfdhfr 108N was 81.9% in patients with malaria
who were treated at the Centre de santé Elizabeth Diouf,
which is similar to the results of those treated in 2009 at
the Hôpital Principal de Dakar (82.4%) [58]. The triple mu-
tation (51 + 59 + 108) increases the risk of in vivo resistance
to sulphadoxine-pyrimethamine by 4.3 (95%CI: 3.0-6.3,
meta-analysis of 22 28-day studies). Isolates carrying a
combination of three mutations (108N, 51I and 59R) were
associated with high-level pyrimethamine resistance and
represented 73.6% of isolates. In 2002, in Dakar, the
prevalence of pfdhfr 108N was 65%, and triple mutants
were identified in 50% of the isolates [33]. In 2003, the
prevalence of mutations in pfdhfr codon 108 was 78% in
Pikine, and the prevalence of the triple mutant was 61%
[88]. Additionally, in 2007, in the rural area Keur Soce,
triple mutants were identified in 67% of patients
treated with sulphadoxine-pyrimethamine combined
with amodiaquine [89].
The pfdhps 437G mutation has been shown to be corre-
lated with in vitro and in vivo resistance to sulphadoxine
[11,17]. The single mutation Ala437Gly and the double mu-
tation Ala437Gly + Lys540Glu increase the risk of in vivo
resistance to sulphadoxine-pyrimethamine by 1.5 (95%CI:
1.0-2.4, meta-analysis of 12 studies) and 3.9 (95%CI: 2.6-5.8,
meta-analysis of 10 studies), respectively [17]. In 2010, theprevalence of the pfdhps 437G mutation was 54.4% in pa-
tients with malaria in Dakar. Only one isolate (0.6%) carried
the double mutation (437G and 540E) that is associated
with high-level sulphadoxine resistance. The mutation of
codon 613 (A613S) (1.2%) is very rare in Africa. In 2002, in
Dakar, only 20% of isolates harboured the pfdhps 437G mu-
tation [33]. In 2003, the mutation rate in pfdhps codon
437G was 40% in Pikine [88]. Several studies from 2006 to
2008 in Senegal showed that the prevalence of pfdhps 437G
significantly increased after intermittent preventive treat-
ment of infants with sulphadoxine-pyrimethamine [89,90].
Given the prevalence of the triple and quadruple mutants
in the population of Dakar (73.6% for the pfdhfr 108N, 51I
and 59R triple mutant and 36.7% for the quadruple mutant
pfdhfr 108N, 51I and 59R and pfdhps 437G), the use of
sulphadoxine-pyrimethamine as an intermittent preventive
treatment (IPT) must be monitored. Encouragingly, only
one quintuple mutant, Pfdhfr 108N, 51I and 59R and
Pfdhps 437G and 540E, which is associated with high-level
sulphadoxine-pyrimethamine resistance has been identified
to date.
IPT with anti-malarial drugs given to all children and
pregnant women once per month during the transmis-
sion season can provide a high degree of protection against
malaria. Seasonal IPT with sulphadoxine-pyrimethamine
and one dose of artesunate resulted in a 90% reduction in
the incidence of clinical malaria in Senegal [6]. The com-
bination of sulphadoxine-pyrimethamine and amodiaquine
was more effective than the combination of sulphadoxine-
pyrimethamine and artesunate or the combination of
amodiaquine and artesunate in preventing malaria
[91]. During IPT with sulphadoxine-pyrimethamine
and piperaquine, only 3.4% of the treated children
developed malaria [89]. However, the single use of
sulphadoxine-pyrimethamine as seasonal IPT is inadvis-
able; for instance, sulphadoxine-pyrimethamine must be
used in combination with amodiaquine, artesunate or
piperaquine [89,92].
The introduction of ACT in 2002 in Senegal did not
induce a decrease in P. falciparum susceptibility to indi-
vidual drug components, such as DHA, MDAQ and
LMF. However, the prevalence of P. falciparum isolates
with reduced drug susceptibility to MQ increased, and
clinical failures with QN have been reported in Senegal.
Additionally, in Senegal, isolates with high IC50 values
for artemisinin derivatives. Since 2004, the prevalence of
chloroquine resistance has decreased, but the data argue
against the re-introduction of chloroquine for mono-
therapy in places where the resistant allele has dropped
to very low levels following discontinuation of chloro-
quine treatment. The prevalence of isolates resistant to
pyrimethamine is high (81.9%), with 73.6% of parasites
exhibiting high-level pyrimethamine resistance. The
prevalence of isolates resistant to sulphadoxine was
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stable between 2009 and 2010 in Dakar. Nevertheless, an
intensive surveillance of the susceptibility of P. falciparum
to anti-malarial drugs in vitro must be conducted in
Senegal. In addition, maximising the efficacy and longevity
of ACT as a tool to control malaria will critically depend on
pursuing intensive research into identifying in vitro markers
as well as implementing ex vivo and in vivo surveillance
programmes. In this context, there is a need to identify
molecular markers that predict ACT resistance, which can
provide an active surveillance method to monitor temporal
trends in parasite susceptibility.
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